|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 4961 | Drugs / Medical | 12/27/2006
Thousands of Pennsylvania doctors may be eligible to join a lawsuit over a Blue Cross health plan's reimbursement rates after a federal judge granted the plaintiffs class-action status.
The suit charges that Keystone Health Plan Central systematically lowered its reimbursement rates to doctors by bundling or changing procedure codes; failing to pay legitimate claims on time; undercounting the number of patients assigned to doctors in the managed-care plan; and other practices. The plaintiffs accuse the health maintenance organization of fraud and racketeering, paralleling a strategy used in suits nationwide over managed-care rates. The lawsuit case involves medical claims dating from January 1996 through November 2001, when the lawsuit was filed on behalf of a Kutztown doctor and her practice group. Keystone Health Plan Central, which serves central Pennsylvania and the Lehigh Valley, was co-owned at the time by Highmark Inc., a Blue Shield affiliate, and Capital Blue Cross. It had more than 6,400 participating physicians in 2001, according to court documents. The lawsuit seeks to represent physicians who were overcharged or not reimbursed by Keystone Health Plan Central. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest A class action has been filed against Watson Pharmaceuticals Inc. (NYSE: WPI) and certain of its officers and directors by stockholders who purchased the company's common stock between November 2, 1999, and November 13, 2001. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. Several class actions have been filed against biotechnology company Biopure Corporation (Nasdaq:BPUR) and certain of its officers and directors by stockholders who purchased the company's common stock between March 17, 2003, and December 24, 2003. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations regarding Biopure’s blood replacement product to the market over this time period, thereby artificially inflating the price of the company's securities. The parties have reached a tentative nationwide $9+ million settlement in a class action filed against Bayer, Inc. on behalf of Canadians who live in any province other than British Columbia, and who were prescribed the anti-cholesterol drug Baycol (cerivastatin) and family members of deceased Canadians who took the drug. The action alleges that the drug causes the serious adverse muscle reaction known as rhabdomyolysis, and may also cause acute renal failure. The court has apparently not yet set a claims deadline-- persons eligible to take part in the settlement should contact attorneys for the class as soon as possible. A class action has been filed against the U.S. companies that produced the herbicide Agent Orange which was used by American forces during the Vietnam War on behalf of Vietnamese people who were indiscriminately exposed to it. The action alleges that it was used as a weapon of mass destruction in violation of the Geneva Convention; that the main ingredient in Agent Orange, dioxin, has caused three million Vietnamese people to suffer from cancer and birth defects; and that large areas of the Vietnamese landscape are still contaminated by dioxin. Numerous drug companies have recently been charged with requesting fraudulent patents. A class action has been filed against Purdue Pharma, LP, the manufacturer of the popular painkiller, OxyContin, on the behalf of purchasers who allege that the company fraudulently secured patents on the drug in an effort to stave off cheaper generic competition. Children are especially susceptible to lead poisoning, which can result in permanent brain damage. A class action has been filed against the Washington, D.C. Water and Sewer Authority (WASA) on behalf of District residents who allege that the Authority has known that their drinking water was contaminated with lead since the summer of 2001, but didn't take any remedial action or notify the public, in violation of federal environmental law. |
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
